Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL post-1L Finite cBTKi+BCL2i ± Obinutuzumab

Trial Identifier: D8220C00036
Sponsor: AstraZeneca
Collaborator:
AbbVie Inc
Genentech, Inc
Start Date: June 2026
Primary Completion Date: May 2029
Study Completion Date: March 2033
Condition: CLL (Chronic Lymphocytic Leukemia)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AT Horn, AT, 3580
BR Goiania, BR, 74605-020
BR Porto Alegre, BR, 90035-903
BR Porto Alegre, BR, 90110-270
BR São Paulo, BR, 1409
BR São Paulo, BR, 01246-000
CZ Brno, CZ, 625 00
CZ Hradec Kralova, CZ, 50005
CZ Ostrava, CZ, 708 502
ES Barcelona, ES, 08041
ES Barcelona, ES, 8035
ES Granada, ES, 18014
ES Madrid, ES, 28041
ES Madrid, ES, 28034
ES Madrid, ES, 28031
ES Majadahonda, ES, 28222
IE Dublin, IE, 7
IE Dublin 8, IE, D08 NHY1
IT MELDOLA, IT, 47014
IT Milano, IT, 20162
IT Padua, IT, 35128
IT Ravenna, IT, 48121
PL Bydgoszcz, PL, 85-168
PL Lublin, PL, 20-090
PL Warszawa, PL, 02-776
PL Warszawa, PL, 02-172
US, MA Boston, MA, US, 02215
US, NC Durham, NC, US, 27705
US, NC Winston Salem, NC, US, 27103